Novavax Inc NVAX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EDT
237.20quote price arrow down-0.07 (-0.03%)
Volume
29,484
Close
237.27quote price arrow up+4.97 (+2.14%)
Volume
2,156,401
52 week range
76.59 - 331.68
Loading...
  • Open231.14
  • Day High239.70
  • Day Low229.50
  • Prev Close232.30
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low76.59
  • 52 Week Low Date11/10/20

Key Stats

  • Market Cap17.672B
  • Shares Out74.48M
  • 10 Day Average Volume4.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change112.78

KEY STATS

  • Open231.14
  • Day High239.70
  • Day Low229.50
  • Prev Close232.30
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low76.59
  • 52 Week Low Date11/10/20
  • Market Cap17.672B
  • Shares Out74.48M
  • 10 Day Average Volume4.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change112.78

RATIOS/PROFITABILITY

  • EPS (TTM)-13.71
  • P/E (TTM)-17.31
  • Fwd P/E (NTM)10.94
  • EBITDA (MRQ)-923.549M
  • ROE (MRQ)-204.26%
  • Revenue (MRQ)1.182B
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-80.37%
  • Debt To Equity (MRQ)57.72%

EVENTS

  • Earnings Date11/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates...
James Young Ph.D.
Chairman
Stanley Erck
President
Rick Crowley
Chief Operating Officer
James Kelly
Chief Financial Officer
Troy Morgan J.D.
Executive Vice President
Address
21 Firstfield Rd
Gaithersburg, MD
20878-1757
United States